Skip to main content
Evidence Snapshot

Prolyl hydroxylase EGLN3

CHEMBL5705 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T11:17:00Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5705
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prolyl hydroxylase EGLN3 as ChEMBL target CHEMBL5705, mapped to UniProt Q9H6Z9. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prolyl hydroxylase EGLN3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5705
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9H6Z9
Prolyl hydroxylase EGLN3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Prolyl hydroxylase EGLN3 matters

As of 2026-09-13

Prolyl hydroxylase EGLN3 is reviewed as Prolyl hydroxylase EGLN3 (UniProt Q9H6Z9); Prolyl hydroxylase EGLN3 shows approved-linked disease relevance led by anemia (phenotype). 3 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 1 approved drug, 177 compounds, and 43 assays, with lead potency reaching pChEMBL 10.8.

Disease context
anemia (phenotype)

Prolyl hydroxylase EGLN3 shows approved-linked disease relevance led by anemia (phenotype). 3 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 3 additional disease programs remain visible in the same card. Linked drugs include MOLIDUSTAT, VADADUSTAT.

Start review with anemia (phenotype) because it currently carries approved-linked support. Linked drugs include MOLIDUSTAT, VADADUSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 1 approved drug, 177 compounds, and 43 assays for this target. The dominant activity type is IC50. CHEMBL3133890 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL3133890 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
1 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Prolyl hydroxylase EGLN3 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9H6Z9, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why anemia (phenotype) is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

177
Total Compounds
43
Total Assays
1
Approved Drugs
IC50: 194.0, KI: 2.0, EC50: 12.0, KD: 16.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3133890
 10.8 Kd —
No preferred name
CHEMBL3133889
 10.8 Kd —
No preferred name
CHEMBL3133891
 10.7 Kd —
No preferred name
CHEMBL20724
 10.3 Kd —
No preferred name
CHEMBL3133888
 10.1 Kd —

Approved Drugs

Structure Compound First Approval
VADADUSTAT
CHEMBL3646221
 2023
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T11:17:00Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5705